Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction

Stroke. 2004 Aug;35(8):1899-902. doi: 10.1161/01.STR.0000131748.12553.ed. Epub 2004 May 27.

Abstract

Background and purpose: There is growing evidence that pharmacologic interference with the renin-angiotensin system may reduce risk of stroke, although the mechanism is unclear. Impaired reactivity of cerebral vessels has recently been recognized as a risk factor for stroke. We examined the effect of the angiotensin-converting enzyme (ACE) inhibitor perindopril on cerebral vasomotor reactivity to acetazolamide in patients with lacunar cerebral infarction.

Methods: We studied a cohort of male patients between 3 and 12 months after lacunar infarction confirmed on computed tomography. Each patient received perindopril 4 mg daily or matching placebo for 2 weeks in a randomized, double-blind, placebo-controlled crossover fashion. A 1-week washout period was observed between dosing periods. Cerebral vasomotor reactivity (increase in middle cerebral artery mean flow velocity in response to intravenous injection of 15 mg/kg acetazolamide) was measured before and after each dosing period using standard Doppler ultrasound techniques.

Results: Twelve patients (mean age 63.2+/-2.3 years) completed the protocol. There was no treatment order effect. Cerebral vasomotor reactivity was significantly greater after perindopril treatment (percent change from baseline +18.8+/-10.1% after perindopril, -4.6+/-4.1% after placebo; P=0.032). Dosing with perindopril did not affect resting cerebral blood flow velocity (percent change from baseline +3.1+/-9.5% after perindopril, -0.6+/-5.4% after placebo), nor was there a change in resting blood pressure (+1.8 mm Hg+/-3.1 after perindopril, +1.4 mm Hg+/-2.5 after placebo).

Conclusions: This study provides evidence of a significant improvement in cerebral vasomotor reactivity induced by perindopril, beyond any effect on blood pressure. The results suggest a possible mechanism for the beneficial effect of ACE inhibition on stroke risk observed in recent clinical trials, and suggest a role for the renin-angiotensin axis in the pathophysiology of subcortical small vessel disease.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Blood Flow Velocity / drug effects
  • Blood Pressure / drug effects
  • Brain Infarction / drug therapy*
  • Brain Infarction / physiopathology
  • Carbonic Anhydrase Inhibitors / pharmacology
  • Cerebrovascular Circulation / drug effects*
  • Cross-Over Studies
  • Double-Blind Method
  • Humans
  • Male
  • Middle Aged
  • Perindopril / pharmacology
  • Perindopril / therapeutic use*
  • Ultrasonography, Doppler, Transcranial

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Carbonic Anhydrase Inhibitors
  • Acetazolamide
  • Perindopril